Carbamazepine Tillomed
Modified-release tablets 200 mg — Antiepileptic & Mood Stabiliser
Quick Facts About Carbamazepine Tillomed
Key Takeaways About Carbamazepine Tillomed
- First-line treatment for focal epilepsy: Carbamazepine is recommended by NICE and international guidelines as a first-line option for focal (partial) seizures in adults and children
- Regular blood monitoring is essential: Full blood count, liver function, and serum sodium levels should be checked before starting and periodically during treatment
- Significant drug interactions: Carbamazepine is a potent enzyme inducer (CYP3A4) that can reduce the effectiveness of many other medications, including oral contraceptives and warfarin
- Genetic testing recommended: HLA-B*1502 screening is recommended for patients of South-East Asian ancestry before starting carbamazepine, due to risk of severe skin reactions
- Do not stop suddenly: Abrupt withdrawal can trigger seizures or status epilepticus — always taper gradually under medical supervision
What Is Carbamazepine Tillomed and What Is It Used For?
Carbamazepine Tillomed is a modified-release tablet containing 200 mg of carbamazepine, an anticonvulsant medication used primarily for epilepsy, trigeminal neuralgia, and bipolar disorder. The modified-release formulation ensures gradual, sustained absorption for consistent blood levels throughout the day.
Carbamazepine belongs to the dibenzazepine class of anticonvulsant drugs and has been used in clinical practice since the 1960s. It remains one of the most widely prescribed antiepileptic medications worldwide. The World Health Organization includes carbamazepine on its Model List of Essential Medicines, recognising its fundamental importance in healthcare systems globally.
Carbamazepine works by stabilising voltage-gated sodium channels in neuronal cell membranes. By blocking excessive, repetitive firing of action potentials in depolarised neurons, it reduces the spread of abnormal electrical activity in the brain that causes seizures. This mechanism also underlies its effectiveness in treating neuropathic pain conditions such as trigeminal neuralgia, where abnormal nerve firing causes intense facial pain.
The modified-release (MR) formulation of Carbamazepine Tillomed is specifically designed to release the active substance gradually over several hours. This provides more stable blood concentrations compared with immediate-release tablets, which can lead to peaks and troughs in drug levels. The steadier blood levels with MR tablets typically result in fewer side effects and more consistent seizure control. It is important to note that modified-release tablets should be swallowed whole and not crushed, chewed, or broken.
Approved indications
Carbamazepine Tillomed is approved for several distinct conditions, each supported by robust clinical evidence:
- Epilepsy: Treatment of partial (focal) seizures with or without secondary generalisation, and generalised tonic-clonic seizures. Carbamazepine is recommended by NICE as a first-line monotherapy for focal epilepsy in both adults and children. It is not effective for absence seizures and may actually worsen them.
- Trigeminal neuralgia: First-line treatment for the severe, stabbing facial pain caused by trigeminal nerve dysfunction. Carbamazepine provides pain relief in approximately 70–80% of patients, typically within 24–72 hours of reaching therapeutic doses.
- Bipolar affective disorder: Used as a mood stabiliser, particularly for patients who do not respond to or cannot tolerate lithium. Carbamazepine is effective in preventing both manic and depressive episodes, with particular efficacy for rapid-cycling bipolar disorder.
- Diabetic neuropathy: Sometimes prescribed off-label for neuropathic pain associated with diabetes, although other agents such as pregabalin and duloxetine are generally preferred first-line.
Carbamazepine Tillomed is a modified-release (MR) formulation. Unlike immediate-release tablets that must typically be taken three or four times daily, MR tablets are usually taken twice daily. The MR formulation provides smoother drug levels with fewer peak-related side effects such as drowsiness and dizziness. Do not switch between different carbamazepine formulations without consulting your doctor, as bioavailability may differ between brands.
What Should You Know Before Taking Carbamazepine Tillomed?
Before starting Carbamazepine Tillomed, your doctor should perform baseline blood tests (full blood count, liver function, serum sodium) and consider HLA-B*1502 genetic testing for patients of Asian ancestry. You must inform your doctor about all other medications, as carbamazepine has extensive drug interactions.
Carbamazepine is a powerful medication that requires careful consideration before initiation. Your prescriber will evaluate your medical history, current medications, and risk factors before determining whether carbamazepine is appropriate for you. Understanding the contraindications and precautions helps ensure safe and effective treatment.
Contraindications
Carbamazepine Tillomed must not be taken in the following situations:
- Hypersensitivity: Known allergy to carbamazepine or any structurally related compound, including tricyclic antidepressants (e.g., amitriptyline, imipramine). Cross-reactivity between carbamazepine and oxcarbazepine occurs in approximately 25–30% of patients.
- Atrioventricular (AV) block: Carbamazepine can slow cardiac conduction and is contraindicated in patients with AV conduction disturbances unless a pacemaker is in place.
- Bone marrow suppression: History of bone marrow depression or a current blood disorder such as aplastic anaemia makes carbamazepine use unacceptably dangerous.
- Acute porphyria: Carbamazepine can precipitate acute attacks in patients with hepatic porphyria.
- MAO inhibitors: Concurrent use with monoamine oxidase inhibitors is contraindicated. MAO inhibitors should be discontinued at least 14 days before starting carbamazepine.
Warnings and precautions
Several important warnings apply to carbamazepine use. Your doctor will discuss these with you and determine the appropriate monitoring schedule:
- Serious skin reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal skin reactions. The risk is highest in the first few months of treatment. The presence of the HLA-B*1502 allele, found primarily in individuals of South-East Asian ancestry (Han Chinese, Thai, Malaysian, Filipino), is strongly associated with carbamazepine-induced SJS/TEN. Genetic screening is recommended before starting treatment in these populations.
- HLA-A*3101 allele: Patients of European and Japanese ancestry carrying the HLA-A*3101 allele have an increased risk of hypersensitivity reactions including SJS, TEN, DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), and maculopapular rash.
- Blood disorders: Carbamazepine can cause aplastic anaemia (estimated incidence 2–5 per million patient-years) and agranulocytosis. Regular full blood count monitoring is essential, particularly in the first year of treatment.
- Hepatic effects: Liver function should be assessed before starting and periodically during treatment. Carbamazepine can cause hepatitis and cholestatic jaundice in rare cases. Treatment should be discontinued if liver function tests become significantly elevated.
- Hyponatraemia: Carbamazepine can cause clinically significant hyponatraemia (low sodium levels), particularly in elderly patients. Serum sodium should be measured before starting treatment and monitored periodically, especially if symptoms of water retention or worsening seizures occur.
- Suicidal ideation: As with all antiepileptic drugs, there is a small increased risk of suicidal thoughts and behaviour. Patients and carers should be alert to signs of depression, suicidal ideation, or unusual changes in mood and behaviour, and seek medical attention promptly.
Abrupt discontinuation of carbamazepine can provoke rebound seizures, including status epilepticus, which is a medical emergency. If treatment needs to be stopped, your doctor will gradually reduce the dose over a period of weeks to months. Never adjust your dose or stop taking carbamazepine without consulting your doctor first.
Pregnancy and breastfeeding
Carbamazepine use during pregnancy requires careful risk-benefit assessment by a specialist. The medication crosses the placenta and is associated with an increased risk of congenital malformations, particularly neural tube defects such as spina bifida. The estimated risk of major malformations with carbamazepine monotherapy is approximately 3–6%, compared with 2–3% in the general population. However, carbamazepine carries a lower teratogenic risk compared with valproate, which should be avoided in women of childbearing potential.
Key recommendations for women of childbearing age taking carbamazepine:
- Folic acid supplementation: All women of childbearing potential taking carbamazepine should receive high-dose folic acid (5 mg daily) to reduce the risk of neural tube defects. This should ideally begin at least three months before conception.
- Contraception: Carbamazepine significantly reduces the effectiveness of hormonal contraceptives (combined pill, mini-pill, implant, patch). Alternative or additional contraceptive methods such as copper intrauterine devices or barrier methods should be used.
- Pregnancy planning: Women who are planning pregnancy should discuss their treatment with a neurologist well in advance. The lowest effective dose of carbamazepine should be used, ideally as monotherapy.
- Vitamin K: Neonates born to mothers taking carbamazepine should receive vitamin K at birth to prevent haemorrhagic disease of the newborn.
Carbamazepine is excreted in breast milk at concentrations approximately 25–60% of maternal plasma levels. Breastfeeding is generally considered acceptable during carbamazepine monotherapy at normal doses, but the infant should be monitored for sedation, poor feeding, and adequate weight gain. The benefits of breastfeeding generally outweigh the small risks in most cases.
How Does Carbamazepine Tillomed Interact with Other Drugs?
Carbamazepine is a potent inducer of cytochrome P450 enzymes (particularly CYP3A4, CYP1A2, and CYP2B6), which means it accelerates the metabolism of many other drugs, reducing their effectiveness. Conversely, CYP3A4 inhibitors can dangerously increase carbamazepine levels. Always inform your doctor and pharmacist about all medications you take.
Drug interactions with carbamazepine are among the most clinically significant of any commonly prescribed medication. Carbamazepine induces its own metabolism (auto-induction), meaning that blood levels may decrease after 2–4 weeks of treatment even at a constant dose. This auto-induction also affects the metabolism of many co-administered drugs, potentially rendering them ineffective.
The extent of enzyme induction by carbamazepine is substantial. Studies have shown that carbamazepine can increase the clearance of co-administered CYP3A4 substrates by 2–4 fold, effectively halving or quartering the blood levels of these drugs. This has profound clinical implications, particularly for medications with narrow therapeutic indices such as warfarin, immunosuppressants, and hormonal contraceptives.
Major interactions
| Drug / Class | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Oral contraceptives | Reduced contraceptive levels | Contraceptive failure, unintended pregnancy | Use non-hormonal or high-dose methods |
| Warfarin | Reduced anticoagulant effect | Risk of thromboembolism | Increase warfarin dose, monitor INR closely |
| Erythromycin / Clarithromycin | Increased carbamazepine levels | Toxicity (ataxia, diplopia, nausea) | Avoid combination or monitor levels |
| Valproic acid | Complex: reduced valproate, variable carbamazepine | Loss of seizure control, increased toxicity | Monitor levels of both drugs |
| Phenytoin | Mutual enzyme induction | Unpredictable changes in levels of both | Frequent therapeutic drug monitoring |
| Ketoconazole / Itraconazole | Increased carbamazepine levels; reduced azole levels | Carbamazepine toxicity; antifungal treatment failure | Avoid combination if possible |
| Lithium | Increased neurotoxic effects | Ataxia, tremor, confusion | Monitor closely for neurotoxicity |
| Ciclosporin / Tacrolimus | Reduced immunosuppressant levels | Organ transplant rejection | Monitor levels, increase dose substantially |
Minor interactions
In addition to the major interactions above, carbamazepine has clinically relevant but generally manageable interactions with numerous other medications:
- Benzodiazepines: Carbamazepine reduces levels of clonazepam, midazolam, and alprazolam. Higher doses may be needed for adequate effect.
- Corticosteroids: Reduced effectiveness of dexamethasone, prednisolone, and methylprednisolone due to increased metabolism.
- Antidepressants: Reduced levels of SSRIs (sertraline, citalopram) and tricyclics. Dose adjustment may be necessary.
- Antipsychotics: Reduced levels of haloperidol, olanzapine, risperidone, quetiapine, and aripiprazole.
- Calcium channel blockers: Reduced levels of felodipine, nifedipine, and diltiazem. Conversely, diltiazem and verapamil can increase carbamazepine levels.
- Grapefruit juice: Can inhibit CYP3A4 in the gut wall and increase carbamazepine absorption, potentially leading to toxicity. Patients should avoid consuming large amounts of grapefruit or grapefruit juice.
- St John’s wort: May reduce carbamazepine levels through additional enzyme induction. Avoid concurrent use.
- Alcohol: Enhanced CNS depression. Alcohol consumption should be minimised during carbamazepine treatment.
Given the extensive drug interactions and auto-induction of carbamazepine, therapeutic drug monitoring (TDM) is an invaluable tool. The target plasma concentration range for carbamazepine is generally 4–12 mcg/mL (17–51 micromol/L). Blood samples should be taken as trough levels, drawn immediately before the next dose. TDM is particularly important when starting treatment, changing doses, adding or removing interacting medications, or if toxicity or poor seizure control is suspected.
What Is the Correct Dosage of Carbamazepine Tillomed?
Carbamazepine Tillomed should be started at a low dose and increased gradually to minimise side effects. For adults with epilepsy, the usual starting dose is 100–200 mg once or twice daily, increasing by 100–200 mg every 1–2 weeks until seizures are controlled, typically at 800–1200 mg daily in divided doses.
The dosing of carbamazepine follows a “start low, go slow” approach to minimise dose-related side effects such as dizziness, drowsiness, and nausea. Because carbamazepine induces its own metabolism (auto-induction), blood levels may fall after the first 2–4 weeks at a stable dose, sometimes necessitating a dose increase. Your doctor will adjust your dose based on clinical response and blood level monitoring.
Modified-release tablets like Carbamazepine Tillomed are typically given twice daily, as the sustained-release mechanism maintains adequate blood levels with less frequent dosing compared with immediate-release formulations. The tablets must be swallowed whole with water and should not be crushed, chewed, or divided.
Adults
Epilepsy
Starting dose: 100–200 mg once or twice daily.
Dose titration: Increase by 100–200 mg every 1–2 weeks.
Usual maintenance dose: 800–1200 mg daily in two divided doses.
Maximum dose: 1600–2000 mg daily (in exceptional cases).
Trigeminal neuralgia
Starting dose: 100–200 mg twice daily.
Dose titration: Increase gradually until pain is relieved, usually 200–400 mg three to four times daily (as immediate-release) or equivalent in modified-release divided twice daily.
Usual maintenance dose: 400–800 mg daily.
Maximum dose: 1200 mg daily.
Bipolar disorder
Starting dose: 200–400 mg daily in divided doses.
Dose titration: Increase gradually according to response.
Usual maintenance dose: 400–600 mg daily.
Maximum dose: 1600 mg daily.
Children
Carbamazepine dosing in children is based on body weight. It is approved for use in children with epilepsy, though its use in other indications in paediatric patients is limited:
| Age Group | Starting Dose | Maintenance Dose | Maximum Daily Dose |
|---|---|---|---|
| 1 month – 5 years | 5 mg/kg daily | 5–20 mg/kg daily in 2–3 doses | 35 mg/kg/day |
| 5–10 years | 100 mg twice daily | 200–600 mg daily in 2 doses | 1000 mg/day |
| 10–15 years | 100–200 mg twice daily | 400–1000 mg daily in 2 doses | 1000 mg/day |
Elderly
Elderly patients are more susceptible to the side effects of carbamazepine, particularly hyponatraemia, cardiac conduction abnormalities, and cognitive impairment. The following adjustments apply:
- Start with the lowest effective dose: 100 mg once or twice daily is recommended as a starting dose.
- Titrate more slowly: Dose increases should be smaller (50–100 mg) and spaced further apart (every 2–4 weeks).
- Monitor sodium levels more frequently: Monthly serum sodium monitoring is advisable in elderly patients, as hyponatraemia can present with falls, confusion, and worsening seizures.
- Check cardiac function: An ECG is recommended before starting carbamazepine in elderly patients to exclude pre-existing conduction abnormalities.
Missed dose
If you miss a dose of Carbamazepine Tillomed, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for a missed one. Missing doses of carbamazepine can lead to a drop in blood levels and may increase the risk of breakthrough seizures. If you frequently miss doses, consider using a pill organiser or setting phone reminders.
Overdose
Carbamazepine overdose can be life-threatening and requires immediate medical attention. Symptoms of overdose may appear 1–3 hours after ingestion and typically include:
- Drowsiness, disorientation, and confusion progressing to coma
- Seizures (paradoxically, despite being an anticonvulsant)
- Nystagmus (involuntary eye movements), diplopia (double vision), and ataxia (loss of coordination)
- Nausea, vomiting, and urinary retention
- Respiratory depression and cardiovascular collapse in severe cases
- Cardiac conduction abnormalities including QRS prolongation
If you suspect a carbamazepine overdose, call your local emergency number or poison control centre immediately. There is no specific antidote for carbamazepine. Treatment is supportive and may include activated charcoal (if given within 1–2 hours of ingestion), cardiac monitoring, and management of seizures and respiratory depression in a hospital setting.
What Are the Side Effects of Carbamazepine Tillomed?
The most common side effects of carbamazepine are dizziness, drowsiness, fatigue, nausea, and ataxia (unsteadiness). These are usually dose-related and often improve with time. Serious but rare side effects include severe skin reactions (Stevens-Johnson syndrome), blood disorders (aplastic anaemia), and liver damage. Report any rash, fever, sore throat, or unusual bruising to your doctor immediately.
Like all medicines, carbamazepine can cause side effects, although not everyone experiences them. Most side effects are dose-related, meaning they are more likely to occur at higher doses and often improve as the body adjusts to the medication or if the dose is reduced. Starting at a low dose and increasing gradually helps minimise these initial side effects.
The modified-release formulation of Carbamazepine Tillomed generally produces fewer peak-related side effects compared with immediate-release carbamazepine, as it avoids the sharp spikes in blood levels that can trigger symptoms such as drowsiness, dizziness, and diplopia. However, the overall side effect profile is similar regardless of formulation.
Understanding the frequency categories used below: “Very common” means more than 1 in 10 people are affected; “Common” means 1 in 10 to 1 in 100; “Uncommon” means 1 in 100 to 1 in 1,000; and “Rare” means fewer than 1 in 1,000. Being aware of these frequencies helps you understand the relative likelihood of each side effect.
Very Common (>1/10)
- Dizziness and vertigo
- Drowsiness and fatigue
- Ataxia (unsteadiness, loss of coordination)
- Nausea and vomiting
- Allergic skin reactions (rash in up to 10% of patients)
- Leucopenia (reduced white blood cell count, usually benign and transient)
- Elevated gamma-GT (liver enzyme, usually clinically insignificant)
Common (1/10 – 1/100)
- Headache
- Diplopia (double vision)
- Blurred vision
- Dry mouth
- Oedema (fluid retention)
- Weight gain
- Hyponatraemia (low blood sodium)
- Elevated alkaline phosphatase
- Accommodation disorders (difficulty focusing)
Uncommon (1/100 – 1/1,000)
- Involuntary movements (tremor, dystonia, tics)
- Nystagmus (involuntary eye movements)
- Diarrhoea or constipation
- Exfoliative dermatitis
- Urticaria (hives)
- Eosinophilia (elevated eosinophil count)
- Elevated transaminases (liver enzymes)
Rare (<1/1,000)
- Stevens-Johnson syndrome (SJS) — potentially life-threatening skin reaction
- Toxic epidermal necrolysis (TEN)
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)
- Aplastic anaemia and agranulocytosis
- Hepatitis, cholestatic jaundice, hepatic failure
- Systemic lupus erythematosus-like syndrome
- Pancreatitis
- Renal failure, interstitial nephritis
- Cardiac conduction disturbances
- Aseptic meningitis
Contact your doctor immediately or go to the nearest emergency department if you experience any of the following: a widespread rash with blisters or peeling skin; unexplained fever with sore throat, mouth ulcers, or bruising; yellowing of the skin or eyes (jaundice); severe abdominal pain; difficulty breathing or swelling of the face; or unusual bleeding or bruising. These may indicate serious adverse reactions that require urgent medical assessment.
How Should You Store Carbamazepine Tillomed?
Store Carbamazepine Tillomed below 25°C in a dry place, protected from light and moisture. Keep the tablets in their original packaging until use. Store out of sight and reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety throughout the shelf life. Carbamazepine is sensitive to moisture and heat, which can affect the stability of the modified-release mechanism and the active ingredient. Degradation of carbamazepine can lead to reduced potency, meaning the medication may become less effective at controlling seizures or pain.
Follow these storage guidelines for Carbamazepine Tillomed:
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze. Avoid exposure to extreme heat, such as leaving tablets in a car during summer.
- Moisture protection: Keep the tablets in their original blister packaging or container until you are ready to take them. Avoid storing in humid environments such as bathrooms.
- Light protection: Carbamazepine is sensitive to light. Store in the original carton to protect from direct sunlight.
- Child safety: Store out of the sight and reach of children. Consider using a locked medicine cabinet, particularly as carbamazepine overdose can be dangerous.
- Expiry date: Do not use Carbamazepine Tillomed after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medications via household waste or wastewater. Return unused or expired tablets to a pharmacy for safe disposal to protect the environment.
What Does Carbamazepine Tillomed Contain?
Each Carbamazepine Tillomed modified-release tablet contains 200 mg of carbamazepine as the active substance, along with excipients that form the modified-release matrix, including ethylcellulose, microcrystalline cellulose, and magnesium stearate.
Understanding the composition of your medication can be important, particularly if you have known allergies or intolerances to specific excipients (inactive ingredients). The modified-release matrix is what distinguishes this formulation from immediate-release carbamazepine tablets and is critical for the controlled, gradual release of the drug.
Active substance: Carbamazepine 200 mg per tablet. Carbamazepine (chemical name: 5H-dibenz[b,f]azepine-5-carboxamide) is a white to off-white crystalline powder with a molecular weight of 236.27 g/mol. It is practically insoluble in water, which contributes to its suitability for modified-release formulations.
Excipients (inactive ingredients): The exact excipient composition may vary slightly between batches but typically includes:
- Ethylcellulose: The primary modified-release polymer that forms the matrix controlling drug release
- Microcrystalline cellulose: A filler and binder that provides structural integrity to the tablet
- Colloidal anhydrous silica: A flow agent used in the manufacturing process
- Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment
- Talc: Used as a glidant and anti-adherent
- Methacrylic acid copolymer: May be included to modify drug release characteristics
Carbamazepine Tillomed modified-release tablets do not typically contain lactose, gluten, or sucrose. However, formulations can vary, and you should always check the patient information leaflet supplied with your specific medication for the most accurate and up-to-date list of excipients. If you have any known allergies to excipients, discuss this with your pharmacist before taking the medication.
Frequently Asked Questions About Carbamazepine Tillomed
Carbamazepine Tillomed is a modified-release tablet containing 200 mg carbamazepine. It is primarily used to treat epilepsy (particularly focal and generalised tonic-clonic seizures), trigeminal neuralgia (severe facial nerve pain), and bipolar disorder (as a mood stabiliser). The modified-release formulation provides steady blood levels throughout the day with twice-daily dosing, reducing the peak-related side effects that can occur with immediate-release formulations.
The most common side effects include dizziness, drowsiness, fatigue, nausea, vomiting, and unsteadiness (ataxia). These are usually dose-related and often improve as the body adjusts. Skin rashes occur in about 10% of patients and should always be reported to your doctor, as rarely they can progress to more serious skin reactions. Other common effects include headache, dry mouth, blurred or double vision, and mild fluid retention.
Yes, carbamazepine has one of the most extensive drug interaction profiles of any commonly prescribed medication. It is a potent enzyme inducer, meaning it speeds up the metabolism of many other drugs. This can reduce the effectiveness of oral contraceptives, warfarin, immunosuppressants, and many other medications. Conversely, drugs like erythromycin, ketoconazole, and grapefruit juice can increase carbamazepine levels to dangerous amounts. Always inform your doctor and pharmacist about all medications, supplements, and herbal products you take.
Yes, regular blood monitoring is an important part of carbamazepine treatment. Before starting, your doctor should perform a full blood count (FBC), liver function tests (LFTs), and serum sodium levels. These should be repeated periodically during treatment — typically every few months in the first year, then at least annually. Therapeutic drug monitoring of carbamazepine blood levels (target: 4–12 mcg/mL) helps ensure the dose is effective without being toxic. Contact your doctor if you develop unexplained fever, sore throat, mouth ulcers, or unusual bruising, as these may indicate a blood disorder.
Carbamazepine carries some risks during pregnancy, including an increased risk of neural tube defects such as spina bifida (approximately 1% risk compared with 0.1% in the general population). However, it has a lower teratogenic risk than valproate and may be continued if the benefits outweigh the risks. Women of childbearing age should take high-dose folic acid (5 mg daily) and discuss pregnancy planning with their neurologist well in advance. Treatment should never be stopped abruptly, as uncontrolled seizures pose serious risks to both mother and baby.
If you miss a dose, take it as soon as you remember unless it is nearly time for your next dose. Do not take a double dose to make up for the missed one. Missing doses can reduce blood levels and increase the risk of breakthrough seizures. If you regularly forget doses, consider using a pill organiser or setting phone alarms. Contact your doctor if you have missed multiple consecutive doses, as a gradual re-titration may be necessary.
References and Sources
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Carbamazepine — Summary of Product Characteristics. EMA Product Information Database. Updated 2024.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults. NICE guideline [NG217]. Updated 2024.
- British National Formulary (BNF). Carbamazepine monograph. NICE Evidence Services. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. Geneva: WHO; 2023.
- Marson AG, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375-1386.
- Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544-556.
- Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clin Pharmacol Ther. 2013;94(3):324-328.
- U.S. Food and Drug Administration (FDA). Tegretol (carbamazepine) prescribing information. Revised 2023.
- Epilepsy Foundation. Carbamazepine. Epilepsy Foundation Drug Reference. Accessed January 2026.
- Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246-252.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in neurology, clinical pharmacology, and epilepsy management. Our team follows international editorial standards and the GRADE evidence framework to ensure accuracy and clinical relevance.
Content created by licensed physicians with expertise in neurology and clinical pharmacology, following EMA, FDA, BNF, and WHO guidelines.
Independently reviewed by the iMedic Medical Review Board to ensure accuracy, completeness, and adherence to evidence-based medicine standards.
Editorial principles: All medical content on iMedic is written by qualified healthcare professionals, reviewed by independent medical experts, and regularly updated to reflect the latest clinical evidence. We receive no pharmaceutical industry funding and maintain strict editorial independence. For more information, see our editorial standards.